Zhao Weiwei, Wang Peng, Jia Huixun, Chen Menglei, Gu Xiaoli, Liu Minghui, Zhang Zhe, Cheng Wenwu, Wu Zhenyu
Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
BMC Cancer. 2017 Aug 2;17(1):514. doi: 10.1186/s12885-017-3498-8.
The lymphocytes played an important role in the natural history of cancer. The aim of this study was to explore the prognostic value of lymphocyte count and percentage for survival in advanced cancer patients receiving palliative care.
A retrospective review of clinicopathological data from 378 consecutive advanced cancer patients and 106 extended follow-up patients treated with palliative care was conducted. Kaplan-Meier curves and multivariate cox regression analyses were used to evaluate the relationships of peripheral lymphocyte count (LC) and lymphocyte to white blood cell ratio (LWR) with overall survival (OS).
The median values for pretreatment LC and LWR were 1.1 (IQR, 0.8 ~ 1.5 × 10/L) and 0.138 (IQR, 0.086 ~ 0.208). The median survival times across LWR quartiles were 19, 47, 79, and 101 days (P < 0.001). Multivariate analysis indicated that patients in the highest quartiles of LC and LWR had an HR of 1.082 (95% CI 0.777 ~ 1.506, P = 0.642) and 0.466 (95% CI 0.328 ~ 0.661, P < 0.001), respectively, compared with patients in the lowest quartiles. Furthermore, only the dynamic changes of LWR were confirmed as an independent prognostic factor for overall survival during the follow-up (HR = 0.396, 95% CI 0.243 ~ 0.668; P = 0.001), as were primary tumor site and ECOG. No effect was observed for the dynamic changes of LC.
Our findings demonstrate that measurement of the dynamic changes of LWR prior to treatment and during follow-up may represent a simple and new powerful prognostic factor for patients with advanced cancer, unlike measurement of LC. As a bedside marker of immune status, the prognostic role of LWR should be further evaluated in prospective studies.
淋巴细胞在癌症自然病程中发挥重要作用。本研究旨在探讨淋巴细胞计数和百分比对接受姑息治疗的晚期癌症患者生存的预后价值。
对378例连续接受姑息治疗的晚期癌症患者及106例延长随访患者的临床病理数据进行回顾性分析。采用Kaplan-Meier曲线和多因素Cox回归分析评估外周血淋巴细胞计数(LC)和淋巴细胞与白细胞比值(LWR)与总生存期(OS)的关系。
治疗前LC和LWR的中位数分别为1.1(四分位间距,0.81.5×10⁹/L)和0.138(四分位间距,0.0860.208)。LWR四分位数组的中位生存时间分别为19、47、79和101天(P<0.001)。多因素分析表明,与最低四分位数组患者相比,LC和LWR最高四分位数组患者的风险比(HR)分别为1.082(95%置信区间0.7771.506,P=0.642)和0.466(95%置信区间0.3280.661,P<0.001)。此外,随访期间仅LWR的动态变化被确认为总生存期的独立预后因素(HR=0.396,95%置信区间0.243~0.668;P=0.001),原发肿瘤部位和美国东部肿瘤协作组(ECOG)评分也是如此。未观察到LC动态变化的影响。
我们的研究结果表明,与LC测量不同,治疗前及随访期间LWR动态变化的测量可能是晚期癌症患者一种简单且有力的新预后因素。作为免疫状态的床旁标志物,LWR的预后作用应在前瞻性研究中进一步评估。